The Neuro-Psychological Axis of Pancreatic Cancer as a Novel Target for Intervention

Hildegard M Schuller

Department of Biomedical & Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN 37996, USA

Abstract

This review summarizes experimental and clinical data in support of the hypothesis that the known risk factors for Pancreatic Ductal Adenocarcinoma (PDAC), smoking, psychological stress, alcohol consumption, diabetes and pancreatitis, create hyperactivity of the neurotransmitters norepinephrine and epinephrine in the pancreas. Smoking, psychological stress and alcohol sensitize the nicotinic acetylcholine receptors (nAChRs) that regulate the synthesis and release of PDAC stimulating stress neurotransmitters norepinephrine and epinephrine by nerves of the sympathetic, the adrenal gland and by pancreatic cancer cells and their epithelial precursor cells while simultaneously desensitizing the nAChRs that govern the synthesis and release of the PDAC inhibiting neurotransmitter g-aminobutyric acid (GABA). Experimental data generated in vitro and in animal models emphasize a key role of G1-coupled β-adrenergic and PGE2 receptors in the activation of multiple signaling pathways by stress neurotransmitters in PDAC. The clinical behavior of PDAC confirms that sympathetic nerves that release stress neurotransmitters are important mediators of PDAC progression. Emerging experimental evidence suggests that lessons learned from the long-term management of cardiovascular disease, which is governed by sympathetic hyperactivity, can be successfully utilized to improve survival rates of PDAC patients and to prevent the development of PDAC in individuals at risk.

Keywords: Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic cancer; Nervous system

Introduction

Cancer of the exocrine pancreas is the fourth leading cause of cancer deaths in developed countries, with a mortality >95% within one year of diagnosis [1]. This cancer is classified as pancreatic ductal adenocarcinoma by histopathology and is therefore referred to as “PDAC” in this review. Smoking, chronic pancreatitis and diabetes are established risk factors for PDAC [2]. More recent findings additionally suggest chronic psychological stress as a risk factor for PDAC [3,4] and PDAC patients demonstrate higher levels of psychological stress than with individuals with other cancers at the time of diagnosis [5]. Chronic abuse of alcohol has also been suggested to increase the risk for PDAC but epidemiological assessments of this association have yielded less conclusive results [6,7]. The mechanisms how these diverse factors increase the risk for PDAC or may negatively impact intervention strategies are poorly understood.

The regulation of cardiovascular function by the autonomic nervous system and interference with this regulatory network by smoking, alcohol abuse and psychological stress have long been recognized as contributing factors to cardiovascular disease [8]. However, information on a potential regulatory role of a similar neuro-psychological axis for PDAC has only recently emerged [9,10].

The autonomic nervous system with its two branches, the sympathetic and parasympathetic (Figure 1), regulates functions of the mammalian organism that are not under voluntary control. Acetylcholine is the neurotransmitter released by the parasympathetic and initiates organ and cellular responses by binding to acetylcholine receptors. These receptors are comprised of two families distinguished by their different abilities to bind nicotine or muscarine [11]. Nicotine has selective high affinity as an agonist for all nicotinic acetylcholine receptors (nAChRs) whereas muscarine is a selective agonist for muscarinic acetylcholine receptors (mAChRs). All nAChRs are ligand-gated ion channels that are enclosed by alpha subunits (α1-α10) alone (“homomeric” α7nAChR) or together with one or more non alpha subunits (β1-β4). The nAChRs expressed at the neuro-muscular junction (α1nAChR) additionally express gamma and/or delta subunits [12]. The five known mAChRs (M 1-M5) form G-protein complexes with G1 or G5 in the cell membrane [13] (Figure 1). The catecholamine neurotransmitters norepinephrine and epinephrine are synthesized by neurons and nerves of the sympathetic in response to binding of acetylcholine to nAChRs. They are also synthesized and released by the adrenal medulla in response to cholinergic stimulation by psychological stress [14], a phenomenon that lead to their classification as "stress neurotransmitters". The stress neurotransmitters initiate cell and organ responses by binding as agonists to adrenergic receptors (Figure 1). These receptors are comprised of two families, the alpha (α-ARs) and beta-adrenergic receptors (β-ARs) [11]. Norepinephrine and epinephrine have similar affinities to the β1-AR whereas norepinephrine has little effects on the β2-AR for which epinephrine is a highly potent agonist. Norepinephrine has higher affinity than epinephrine to the α1-AR [15,16] whereas both catecholamines have similar affinities to the α2-AR [15]. The α-1AR is coupled to the G-protein Gα that activates phospholipase C (PLC), inositol three phosphate (IP3) and Diacylglycerol (DAG), thereby increasing intracellular Ca2+ [17] (Figures 1 and 2). The α2-AR is coupled to the inhibitory G-protein Gi that inhibits the formation of intracellular cAMP by inactivating adenyl cyclase [17] (Figure 2). All three known β-ARs (β1-3) are coupled to the stimulatory G-protein Gs, while the β2-AR is additionally coupled to G1 [17,18] (Figure 1). The stimulatory G-protein Gs activate adenyl cyclase [17,18] (Figure 2), the single
In PDAC cells (Figure 2) [37]. In addition to β-ARs, the cAMP/PKA downstream of beta-adrenergic signaling is also increased via cAMP-mediated increase in vascular endothelial growth factor (VEGF) and arachidonic acid (AA). COX-2 [36] are frequently over-expressed in human PDAC tissues. 

Angiogenesis is also increased via cAMP-mediated increase in vascular endothelial growth factor downstream of beta-adrenergic signaling in PDAC cells (Figure 2) [37]. In addition to β-ARs, the cAMP/PKA cascade is activated by the two Gs-coupled receptors (EP2, EP4) [32] for prostaglandin E2 (PGE2; Figure 2) that is formed from AA by COX-2.

Selective pharmacological blockage of β2-ARs synergized with the leading PDAC therapeutic gemcitabine to induce apoptosis via inhibition of transcription factor nuclear factor kβ (NF-kβ) activation and down regulation of Bcl-2 protein in PDAC cell lines BXPC-3 and Mia PaCa-2 in vitro while additionally inhibiting cell proliferation and invasion via reduction in CREB, NF-kβ and activator protein 1 (AP-1) [38]. A selective β2-AR antagonist also effectively induced apoptosis associated reduction in of caspase3 and caspase 9 expressions in PDAC cell line PC-2 [39]. Another laboratory reported significant stimulation of PDAC proliferation associated with induction of p-ERK in the human PDAC cell line Panc-1 in vitro and in mouse xenografts by the selective β-AR agonist isoproterenol and these responses were blocked by the broad-spectrum β-AR antagonist propranolol [24].

PDAC cells and pancreatic duct epithelial cells additionally synthesize and release the amino acid neurotransmitter γ-aminobutyric acid (GABA) [40] and they express the Gs-coupled GABA-B receptors, GABA-B-R1 and GABA-B-R2 [34]. Similar to its role as main inhibitory neurotransmitter in the nervous system, GABA inhibits rate-limiting step required for the formation of intracellular cyclic adenosine monophosphate (cAMP). In turn, cAMP activates protein kinase A (PKA), which activates a number of different downstream effectors in a cell type-specific manner.

PDAC cells express multiple nAChRs [19], mAChRs [20], α1-, α2- [21], β1- and β2-ARs [22-24]. These cells are therefore highly susceptible to intracellular signals initiated by these neurotransmitter receptors in response to autonomic nervous system-mediated release of their respective agonists and systemic increases in norepinephrine and epinephrine in response to psychological stress (Figure 1). In addition, numerous epithelial cells and cancers with phenotypic features of such epithelia have the ability to synthesize and release acetylcholine [25] as well as norepinephrine and epinephrine [19,26-28] and express the required neurotransmitter receptors, providing them with the ability for self regulation in an autocrine fashion. PDAC cells thus synthesize and release acetylcholine [29] that in turn stimulates the synthesis and release of norepinephrine and epinephrine [19]. The resulting increase in intracellular cAMP downstream of b-ARs, activates PKA, stimulating the Arachidonic Acid (AA) cascade via the release of AA [22] while simultaneously activating the Epidermal Growth Factor Receptor (EGFR) pathway via transactivation of the EGFR [30] and by cAMP-dependent release of its two agonists, EGF [31] and amphiregulin [32] (Figure 2). Activated PKA additionally activates the transcription factor Cyclic Adenosine Response Element Binding Protein (CREB) directly via phosphorylation [19,33] (Figure 2) while reported PKA-dependent activations of Extracellular Signal Regulated Kinases (ERK) AKT and Src [19] were likely triggered via the EGFR pathway (Figure 2). In accord with these in vitro findings, norepinephrine, activated PKA, p-CREB [34], the EGFR [35] and the AA-metabolizing enzyme cytochromeoxidase 2 (COX-2) [36] are frequently over-expressed in human PDAC tissues. Angiogenesis is also increased via cAMP-mediated increase in vascular endothelial growth factor downstream of beta-adrenergic signaling in PDAC cells (Figure 2) [37]. In addition to β-ARs, the cAMP/PKA
the β-adrenergic cancer-stimulating signaling cascades in PDAC cells by binding to GABA-B-Rs, causing G-mediated inhibition of cAMP formation (Figure 2) [34,40]. In vitro and in vivo experiments have shown that GABA has powerful anti-cancer effects on PDAC by inhibiting cell proliferation, migration and angiogenesis via this mechanism [10,34,37]. Immunohistochemical investigations of human PDAC tissue microarrays have shown that GABA is frequently suppressed whereas norepinephrine is overexpressed [34], suggesting that the absence of cAMP-inhibition via this neurotransmitter in PDAC may significantly contribute to the development and progression of this cancer.

The current review summarizes experimental evidence in support of the hypothesis that all known risk factors for PDAC modulate important components of the neuro-psychological regulatory axis of this cancer illustrated in Figure 3 and that PDAC intervention strategies need to address this issue in order to become more successful.

Effects of Tobacco Constituents on Pancreatic Cancer

Nicotine is generally thought to be responsible for the addictive properties of cigarette smoke and other tobacco products. Nicotine addiction is mediated by nicotine-induced changes in the expression and function of brain nAChRs. Chronic exposure to nicotine increases the protein expression of all nAChRs via several post-transcriptional and post-translational mechanisms without changes in expression levels of mRNA [41]. In the case of the homomeric (comprised only of alpha subunits) α7nAChR, this protein up regulation is accompanied by sensitization of the receptor whereas the heteromeric α4b2nAChR is desensitized [12]. These different responses to chronic nicotine are generally attributed to the high affinity of nicotine for the α4b2nAChR as opposed to a comparatively lower affinity for the α7nAChR. The brain homomeric α7nAChR regulates the synthesis and release of the excitatory neurotransmitters norepinephrine, epinephrine, serotonin, dopamine and glutamate [42] whereas the heteromeric (comprised of alpha plus non-alpha subunits) α4b2nAChR regulates the synthesis and release of the inhibitory neurotransmitter GABA. Diabetes suppresses pancreatic GABA levels by reducing the number of 38 functional beta cells in pancreatic islets that are a major source of pancreatic GABA. Pancreatitis suppresses pancreatic GABA by replacing GABA-producing pancreatic epithelial cells by fibro-inflammatory tissues.

It has long been recognized that metabolites of the two nicotine-derived carcinogenic nitrosamines N-nitroso-nicotine-ketone (NNK) and N-nitroso-nornicotine (NNN) cause activate point mutations in Ras inactivating mutations in the tumor suppressor gene p53, with NNK being the more potent mutagen [43]. In light of the key role of Ras in the EGFR pathway (Figure 2) which is often mutated in human
PDACs [44], it was therefore initially believed that these mutations are the sole driving forces of smoking-associated cancers, including PDAC. However, receptor-binding assays have additionally shown that NNK and NNN are nAChR agonists, with NNK having a 1000-fold higher affinity than nicotine to the α7nAChR and NNN having a 4000-fold higher affinity than nicotine to the α4β2nAChR [45,46]. These direct interactions of NNK and NNN with nAChRs therefore significantly contribute to both, smoking-associated carcinogenesis and addiction. NNK is additionally an agonist for β-ARs with significantly higher affinity than norepinephrine for β1-ARs and significantly higher affinity than epinephrine for β2-ARs [47], thus further intensifying its PDAC stimulating effects via the regulatory cascade shown in Figure 3 and 4. While nAChRs were initially thought to be specific receptors expressed only in the central and peripheral nervous system and at neuro-muscular junctions, it is now understood that they are ubiquitously present in all mammalian cells where they regulate a host of different functions in a cell type-specific manner [48]. In vitro studies have shown that binding of acetylcholine or NNK to nAChRs with subunits α3, α5, and α7 jointly stimulated cell proliferation and migration of PDAC cells and immortalized pancreatic ductal epithelial cells by activating the synthesis and release of norepinephrine and epinephrine [19]. The two stress neurotransmitters then triggered the activation of a complex signaling cascade downstream of G- coupled β-ARs in a cAMP-dependent manner [19] (Figure 2). Under physiological conditions, the signaling responses to stress neurotransmitters in the pancreas are counterbalanced by α4β2nAChR-mediated synthesis and release of GABA that in turn binds to the G- coupled GABA-B-Rs, thus blocking the activation of adenyl cyclase (Figure 2). However, even single-dose exposures to nicotine or NNK suppressed GABA production by desensitizing the α4β2nAChR [40]. Chronic (7 days) exposure of the cells to acetylcholine, nicotine or NNK significantly increased the protein expression of all nAChRs in PDAC and pancreatic duct epithelial cells [40]. Compared with cells exposed only to a single dose of these nAChR agonists, production of stress neurotransmitters was significantly increased and the cells additionally responded to lower concentrations of agonist, indicative of a sensitized α7nAChR. By contrast, GABA production was significantly suppressed below the levels observed with single doses of agonist [40]. Phosphorylated signaling proteins ERK, Src, AKT and CREB downstream of β-ARs as well as vascular endothelial growth factor and COX-2, all of which are frequently over expressed in human PDAC tissues, were significantly induced by the observed changes in nAChR expression and function [37,40]. It hence appears that the observed in vitro responses of PDAC cells to chronic nicotine or NNK were the equivalent of molecular events in the brain responsible for nicotine addiction. While such nAChR modulations in the brain affect cognition and mood, they significantly increase proliferation, migration and angiogenesis in PDAC. Addition of GABA to the culture media completely abrogated all nAChR agonist-induced modulations in the protein expression and function of nAChRs α3, α4, α5 and α7, reducing cancer-stimulating signaling cascades below base levels observed in control cells [40]. Studies in mouse PDAC xenograft models fully supported these in vitro findings by showing strong promotion of PDAC growth associated with increased expression of the same signaling proteins induced by nicotine or NNK in vitro when the mice were given chronic nicotine (200 mg/ml for 4 weeks) in the drinking water. Treatment of the mice by GABA injections completely blocked all of these responses to nicotine [49]. In support of these experimental findings, it has been shown that smoking suppresses the mammalian GABA system as a whole [50] while pancreatitis [51] and diabetes [52] both reduce GABA production locally in the pancreas. These three risk factors for PDAC thus share adverse effects on PDAC inhibiting GABA signaling, a fact that may significantly contribute to their positive etiological association with PDAC. In addition, smoking increases the systemic levels of stress neurotransmitters via nAChR-mediated release from the adrenal gland and nerves of the sympathetic [8], which helps explain why smoking is the strongest known risk factor for PDAC.

NNK caused PDAC development in hamsters with ethanol-induced pancreatitis [53] and the tumor tissues showed increased protein expression of the α7nAChR, activated PKA, p-CREB, p-ERK, COX-2 and VEGF whereas the general β-AR antagonist (beta-blocker) propranolol prevented the development of PDAC in this animal model [54]. These experimental in vivo findings further emphasize the key role of signaling downstream of β-ARs in the development and progression of PDAC. Studies with this hamster model of PDAC additionally showed that the non-steroidal anti-inflammatory agent ibuprofen, that blocks the formation of COX-2, dependent metabolites from arachidonic acid, partially prevented the development of PDAC [55]. As illustrated in Figure 3 and 4, β-ARs are upstream regulators of the AA-cascade but additionally regulate the EGFR pathway, the PKA/CREB pathway and angiogenesis in PDAC, providing an explanation why the beta-blocker propranolol more effectively prevented PDAC than ibuprofen.

Recent investigations in a transgenic mouse model of PDAC with constitutively activated K-ras have shown that chronic treatment of the mice with low dose aspirin significantly prevented the progression of intraepithelial lesions to overt PDAC, a response associated with reduction in COX-2 expression [56]. This was a landmark finding because it documents that the mutated K-ras, although a downstream effector in the AA cascade and EGFR cascade of PDAC, can nevertheless be controlled by the upstream inhibition of COX-2-dependent AA metabolites. Beta-blockers or G-mediated inhibition of adenylyl cyclase would likely have even greater PDAC preventive potency in this mouse model and in human PDACs that express mutated K-ras.

Animal experiments typically use nicotine in the drinking water at a dose of 200 mg/ml (432 mM/L) to approximate the blood nicotine concentrations observed in heavy smokers. The dose of nicotine significantly increased the growth of PDAC xenografts in mice when administered to the animals over a 4-week period [49]. By contrast, the descending doses of nicotine contained in Nicotine Replacement (NRT) products yield significantly lower systemic nicotine concentrations. These products were therefore initially considered as “safe” alternatives to smoking and are in fact utilized by many nicotine addicts as long-term tools to satisfy their habit. In addition, PDAC therapy in smokers is often accompanied by treatment with NRT products to eventually eliminate the causative factor smoking. However, the sensitization of the α7nAChR with concomitant desensitization of the α4β2nAChR observed in PDAC cells exposed for 7 days to 1 mM nicotine in vitro [40] suggest that nicotine concentrations significantly below the blood levels observed in heavy smokers may have adverse effects on the clinical outcomes of PDAC therapy. In support of this hypothesis, a recent study with mouse xenografts from PDAC cell lines showed that low dose nicotine (1 mM/L in the drinking water) significantly increased the resistance of PDAC to gemcitabine when administered to the animals for 4 weeks [57]. This effect of nicotine was associated with a reduction in gemcitabine-induced caspase 3 and apoptosis while additionally inhibiting the gemcitabine-induced reduction in the levels of multiple phosphorylated signaling proteins, including ERK, Src and AKT [57]. These findings suggest that even moderate smoking or NRT may negatively impact clinical outcomes of gemcitabine therapy in...
PDAC patients. In light of the fact that gemcitabine is the leading PDAC therapeutic and is often accompanied by NRT, the observed induction of gemcitabine resistance by low dose nicotine may significantly contribute to the documented poor prognosis of this cancer.

Numerous publications have reported PDAC stimulating effects of nicotine in vitro and in animal models. It has thus been shown that nicotine induced PDAC cell migration in vitro via α7nAChR-mediated upregulation of the MUC4 mucin associated with activation of JAK2/STAT3, ERK and Src [58]. In accord with these findings, exposure to cigarette smoke significantly increased the size of orthotopically implanted PDAC xenografts in mice accompanied by increased expression of MUC4, α7nAChR and p-STAT3 in the tumor tissue [58].

Another study reported induction of Src-dependent differentiation-1 inhibitor transcription factor by nicotine in PDAC cells in vitro and inhibition of orthotopically implanted PDAC xenografts by gene knockdown of this transcription factor [59]. Another laboratory reported α7nAChR-mediated induction of the secreted phospho-protein osteopontin that is associated with cell migration, by nicotine in PDAC cells in vitro and showed expression of osteopontin in the majority of investigated PDAC tissue samples from smokers [60,61]. Moreover, it was shown that NNK caused dose-and time-dependent increases in the proliferation and migration of PDAC cells BxPC-3 and MIAPACA-2 accompanied by increases in FAK and ERK activation and inhibited by the beta-blocker propranolol or the cruciferous vegetable flavone Apigenin [62]. In addition, immortalized pancreatic duct epithelial cells exposed in vitro to cigarette smoke or NNK responded with AKT-dependent reduction in apoptosis while autophagy was stimulated [63]. The modulation of signaling proteins and transcription factors in response to nicotine in the cited publications were frequently interpreted as effects immediately downstream of nAChRs. However, the discovery that PDAC cells and pancreatic duct epithelial cells produce norepinephrine and epinephrine in response to nicotine [19] indicates that most of these responses were indirectly caused by binding of nicotine-induced stress neurotransmitters to b-ARs (Figure 4).

Effects of Psychological Stress on PDAC

High levels of psychological stress are associated with increased cancer mortality and PDAC patients showed higher levels of stress than patients with cancers at other organ sites [3-5]. As pointed out in the introduction, the stress neurotransmitters norepinephrine and epinephrine are agonists for alpha and beta-adrenergic receptors. The important regulatory function of b-ARs in PDAC cells (Figure 3 and 4) therefore suggests that psychological stress may promote the development and progression of this cancer. In support of this hypothesis, the growth of subcutaneous mouse xenografts from PDAC cell lines Panc-1 (with activating point mutations of K-ras) and BxPC-3 (without ras mutations) was significantly increased by exposure of the mice to social stress for 4 weeks [10]. The stress-induced xenograft progression was accompanied by significant increases in the protein expression of nAChRs α3, α4, α5, α6 and α7, p-ERK, p-AKT, p-Src and p-CREB in the xenografts as well as increases in plasma and tumor tissues of cortisol, norepinephrine, epinephrine, and VEGF and of cAMP in the cellular fraction of blood [10]. By contrast, the protein expressions of the two glutamate dehydrogenase isozymes GAD 65 and GAD 67, which catalyze the formation of GABA from glutamate, were significantly reduced [10]. In accord with this finding, the levels of GABA in plasma and in xenograft tissues were suppressed. Treatment of the mice with GABA abrogated stress-induced tumor growth while blocking stress-induced increases in cAMP, VEGF, and in the protein induction of all investigated signaling proteins. In addition, GABA significantly reduced tumor growth and the levels of all of these effectors in mice not exposed to stress [10]. A follow-up study with the same mouse models revealed that the observed PDAC stimulating effects of social stress on xenograft growth, levels of neurotransmitters, cAMP and VEGF and on expression of signaling proteins was highly reproducible [37]. In addition, these experiments showed that the levels of the AA metabolite PGE2 were significantly increased by social stress in plasma and xenograft tissues, a response accompanied by significant increases in COX-2 in the xenografts [37]. Treatment of the mice with the selective COX-2 inhibitor celecoxib significantly decreased all of these responses to social stress while combination treatment with celecoxib and GABA further enhanced the inhibition of all investigated PDAC stimulating effects of social stress [37]. In vitro experiments with Panc-1 and BxPC-3 cells corroborated these findings by showing that exposure of the cells for 7 days to epinephrine at the concentration (15 nM) measured in xenografts of social stress-exposed mice increased cell proliferation more than 2-fold in both cell lines while additionally increasing cell migration more than 4-fold [37]. Celecoxib (1 μM) completely abrogated both effects of epinephrine while additionally significantly reducing base level proliferation and migration of cells not exposed to epinephrine [37]. Collectively, these data strongly support the hypothesis that psychological stress promotes the development and progression of PDAC via cAMP-dependent signaling downstream of β-ARs and PGE2 receptors (Figure 2 and 3) and is in accord with in vitro findings on the regulatory role of β-ARs in PDAC cells [22-24,30].

Several laboratories have investigated stimulating effects of the stress neurotransmitter norepinephrine on PDAC cell proliferation and migration in vitro. It has thus been shown that norepinephrine significantly induced the proliferation of Panc-1 cells in a concentration-dependent manner while increasing S-phase population and decreasing G1 and G2-phase populations accompanied by significant increases in cell migration and invasion in scratch wound healing and in transwell Matrigel assays [64]. These responses were accompanied by induction of p38/MAPK. All reported effects of norepinephrine were completely blocked by the beta-blocker propranolol [64]. These findings are in accord with a report from another laboratory that norepinephrine-induced invasion (tested by Matrigel assay) accompanied by increases in MMP-2, MMP-9 and VEGF and inhibited by propranolol in PDAC cell lines BxPC-3 and MiaPaCa2-2 [65]. One of the putative precursor cells of PDAC, pancreatic duct epithelial cell, also responded to norepinephrine in vitro by cell proliferation associated with increases in interleukin-6 (IL-6) and VEGF [66]. Interestingly, the effects of norepinephrine on cell proliferation and IL-6 were significantly inhibited by the dietary agent sulforaphane from cruciferous vegetables whereas the increase in VEGF remained unchanged. By contrast, a recent publication has reported that a high concentration (10 μM) of norepinephrine inhibited migration in PDAC cell lines Panc-1, MiaPaCa2 and CPAC1 in a three-dimensional collagen-based migration assay that monitors the locomotion of cells without the influence of cell proliferation [67]. Cell proliferation was also inhibited by this concentration of norepinephrine and both responses were significantly reduced by the selective β1-AR antagonist, atenolol or by propranolol [67]. The observed inhibitory actions of norepinephrine were accompanied by excessive increases in intracellular cAMP (up to 4,000-fold) and activation of phospholipase C gamma and protein kinase C alpha [67]. Recent findings from another laboratory provide a potential explanation for these controversial findings by showing concentration-dependent stimulation of proliferation and migration by low concentrations of norepinephrine in PDAC cell lines BxPC-3 and MiaPaCa2 whereas concentrations of 1 μM and above inhibited both responses [68]. According to the National Library of Medicine normal
levels of norepinephrine in tests of human blood samples range from 0 to 600 pg/ml equivalent to a maximum concentration of 2.9 nM [69]. The plasma and xenograft levels of norepinephrine in control mice were in that range and increased to a 10 nM concentration when the animals were exposed for 4 weeks to social stress that significantly promoted the growth of PDAC xenografts [10,37]. The blood levels of norepinephrine are increased about 50-fold in patients with severe heart failure [70]. By contrast, the 10 μM concentration of norepinephrine that inhibited PDAC cell proliferation and migration in vitro [67] represents a 3,500-fold increase of this neurotransmitter above maximum normal blood levels. This high norepinephrine concentration and associated excessive cAMP levels may have switched signaling downstream of the β2-AR from its stimulatory G-protein Gs to its inhibitory G-protein Gi, a phenomenon that has been described in the myocard in response to high circulating epinephrine levels [71]. The classic function of the Gs protein coupled to the β2-AR is the preservation of AMP homeostasis by inhibiting the excessive activation of adenylyl cyclase downstream of simultaneously expressed β1- and β2-ARs [72,73]. Moreover, Gs coupled to the β2-AR activates several cAMP-independent signaling pathways, including PLC/PKC [73] which can reduce cAMP-dependent signaling by inhibiting its effector PKA [74] (Figure 2). Alternatively, the presence of α1 and α2-ARs coupled to Gs and Gi, respectively, in PDAC cells (Figure 1) for which norepinephrine has a high affinity, may have contributed to the observed signaling through PLC and PKC (Figure 2). Maintenance of the PDAC cells in antibiotics may have further contributed to aberrant signaling as antibiotics modulate the proteome of cells in culture [75].

Clinical evidence for an important role of norepinephrine and epinephrine in the progression of PDAC comes from observations that nerves of the sympathetic mediate enhanced PDAC cell chemoattraction and motility via release of these neurotransmitters, resulting in neural invasion and the associated neuropathic pain syndrome [76]. The underlining mechanisms of this clinical phenomenon have recently been investigated by co-culture of mouse dorsal root ganglia with PDAC cells (maintained without antibiotics) in vitro and in a mouse model of perineural invasion [77]. The investigators showed that PDAC cells MiaPaCa-2 and BXPC-3 invaded the dorsal root ganglia in vitro, an effect enhanced in a concentration-dependent manner by exogenous addition of norepinephrine, with a steep increase in response from 0.1-1 μM/L, reaching near saturation at 10 μM/L. These responses were associated with activation of Stat3, AKT, CREB, MMP2 and MMP9 and were inhibited by propranolol. Mice with perineural invasion of the sciatic nerve by surgically implanted PDAC cells had higher norepinephrine levels than mice with sham operations and the perineural invasions were significantly inhibited by treatment of the mice with a Stat-3 blocker [77].

**Effects of Alcohol on PDAC**

The etiological association of chronic alcohol intake with the risk for PDAC is less conclusive than the epidemiological data on smoking as a risk factor [6,7], possibly because many smokers also drink. However, investigations on the association of alcohol intake with PDAC in never smokers showed a significant increase in PDAC risk in never smokers. This effect was limited to the chronic consumption of liquor but was not seen with beer or wine [78].

It is well established that pancreatitis from any etiology, including alcoholism, is an independent risk factor for PDAC [2]. Apart from inflammatory mediators of the AA-cascade involved in this disease, the reduction in systemic GABA levels reported in patients with pancreatitis [51] may significantly contribute to the development of PDAC (Figure 4).

Only few investigations have addressed potential direct effects of ethanol on PDAC cells or their putative cells of origin. It has thus been shown that immortalized pancreatic duct epithelial cells in vitro respond to a single dose of ethanol at a concentration of 17 mM (equivalent to the legal blood alcohol limit in the U.S.) with an increase in intracellular cAMP and increased cell proliferation associated with a significant induction of p-ERK1/2 [33]. This ethanol treatment also significantly enhanced these responses to the nicotine-derived tobacco carcinogen NNK [33]. A recent study using the same ethanol concentration over a 7-day exposure period in PDAC cells Panc-1 and BXPC-3 and in immortalized pancreatic duct epithelial cells reported significant induction in the protein expression of nAChRs with subunits α3, α5, and α7. This response was accompanied by significant increases in the synthesis and release of norepinephrine and epinephrine by the cells, increased levels of intracellular cAMP and activated PKA associated with increases in phosphorylated ERK, AKT, Src and CREB and enhanced proliferation and migration [79]. Gene knockdown of nAChR subunits α3, α5, or α7 each significantly reduced these effects of chronic ethanol whereas simultaneous exposure for 7 days to GABA (30 μM) and ethanol inhibited all of these responses to ethanol. These findings are in accord with the observation that low concentrations (100 μM – 10 mM) of ethanol potentate the response of multiple neuronal nAChRs to their physiological agonist acetylcholine [80], a phenomenon thought to contribute to alcohol dependence [81]. Using a higher concentration (217 mM) of ethanol, another laboratory showed increased cell invasion associated with significant up regulation of the transcription factor Snail in immortalized pancreatic duct epithelial cells in vitro whereas identical exposure of PDAC cell line Panc-1 only yielded minimal induction of Snail and failed to increase cell migration [82].

The mechanistic aspects of alcohol in the development of PDAC suggested by the in vitro investigations summarized above is supported by findings that exposure of pregnant hamsters to ethanol (10%) in the drinking water and NNK (50 mg/kg as a single subcutaneous injection on the last day of pregnancy) caused the development of PDAC in 60% of the offspring and that treatment of the offspring with the beta-blocker propranolol effectively prevented PDAC development [53,54]. NNK is a weak pancreatic carcinogen when administered as a single agent to rats [83] but does not by itself induce the development of this cancer in hamsters, suggesting significant PDAC promoting effects of alcohol ingestion in smokers.

**Conclusions and Future Directions**

The data compiled in this review support the hypothesis that adaptive changes of the autonomic nervous system induced by smoking, chronic psychological stress and habitual ingestion of liquor-strength alcohol play a key role in the development, progression and resistance to therapy of PDAC and occur mostly via protein induction associated with sensitization (α7nAChR) or desensitization (α4nAChR) of nAChRs that regulate the synthesis and release of stress neurotransmitters and GABA, resulting in hyperactivity of Gα-mediated cAMP signaling. These PDAC promoting effects are further intensified by identical changes occurring in nAChRs expressed in PDAC cells and their normal epithelial precursor cells. Activating point mutations in k-ras and inactivating mutations in p53 caused by tobacco carcinogens further enhance the cancer-causing potency of these changes because these mutated genes are downstream components of multiple signaling pathways activated by cAMP/PKA. The resulting systemic and cellular
predominance of PDAC-stimulating stress neurotransmitters with simultaneous suppression of inhibitory GABA destroys the homeostasis of cellular signaling pathways required to maintain a healthy pancreas (Figure 4). Diabetes and pancreatitis also negatively impact the balance between PDAC stimulating and inhibiting neurotransmitters by suppressing the production of pancreatic GABA, thus facilitating the development and progression of PDAC.

The sympathetic branch of the autonomic nervous system and the associated signaling of stress neurotransmitters via β-ARs are increasingly being recognized as an important therapeutic target for several epithelial cancers [9,77,84-86]. There is however conflicting clinical evidence on the effects of beta-blockers on cancer survival. Beneficial effects of beta-blocker therapy has been reported in patients with non-small-cell lung cancer [87], breast cancer [88,89], prostate cancer [90] and melanoma [91]. On the other hand, the use of beta-blockers was associated with a significantly reduced chance of death in patients with ovarian cancer in one study [92] whereas another report showed no significant effects [93]. A recent investigation by Dr. Shah’s group that compared the effects of beta-blockers (primarily selective β1-AR antagonists) with that of other anti-hypertensive agents on clinical outcomes in several different types of cancer reported no significant benefits of beta-blockers on survival of patients with lung cancer and breast cancer while individuals with cancer of the prostate or pancreas even showed significantly poorer survivals than patients treated with non-beta-blocker antihypertensive agents [94]. Much of this ongoing controversy is caused by the complex long-term effects of beta-blockers that differ greatly with duration and dose of treatment and additionally vary among agents that selectively block only the β1-AR versus a general beta-blocker or antagonists with partial agonist function. However, when critically reviewing these data, it is important to remember that sympathetic nerve hyperactivity with the associated increased plasma levels of norepinephrine is a major driving force of cardiovascular disease [95]. Accordingly, many anti-hypertensive agents other than beta-blockers inhibit sympathetic nerve activity. While beta-blockers inhibit sympathetic nerve activity by inhibiting the binding of its released neurotransmitters norepinephrine and epinephrine to β-ARs, inhibitors of the angiotensin/renin system as well as imidazoline receptor agonists inhibit norepinephrine release from sympathetic nerves [95]. Moreover, Ca2+-channel blockers, that are also frequently used for the therapy of hypertension, have strong desensitizing effects on beta-blockers in cancer patients are hampered by the fact that they were conducted in individuals receiving incidental antihypertensive therapy and therefore suffered from pre-existing sympathetic nerve hyperactivity. Clinical trials need to be conducted to test each antihypertensive agent with known sympathetically-inhibiting potency as well as Ca2+-channel blockers that desensitize the α7nAChR in non-hypertensive PDAC patients receiving standard cancer therapy to assess the potential usefulness of this class of agents on survival and responsiveness to therapy. Such studies should be accompanied by regular measurements of systemic stress neurotransmitters, GABA and CAMP levels and should also include testing for single nucleotide polymorphisms of the β2-AR that have recently been identified as a biomarker for PDAC progression and survival [100].

The reported strong anti-cancer effects of GABA in PDAC cells in vitro and in mouse xenografts in the presence and absence of nicotine or psychological stress are highly encouraging. Currently used non-cytotoxic cancer therapeutics such as EGFR tyrosine kinase inhibitors, Src inhibitors or COX-2 inhibitors as well as potentially to be used beta-blockers, aim to block defined components of cancer-stimulating signaling pathways. By contrast, treatment with GABA raises the plasma and tumor levels of this physiological inhibitor of cAMP-dependent signaling so that cAMP homeostasis is restored despite of increased levels of stress neurotransmitters, PGE2 or any other agents that activate adenylyl cyclase. This approach is reminiscent of the strategy to compensate for high blood levels of bad cholesterol by dietary increase in good cholesterol and is particularly appealing because GABA has safely been used for many years as a nutritional supplement. However, there appears to be a subset of PDAC cases that over express the β2-subunit of the GABA-A receptor, thereby converting GABA from an inhibitory into an excitatory neurotransmitter with PDAC promoting effects [101]. GABA should therefore only be used in individuals with normal expression levels of GABA-A receptor subunits.

Findings that celecoxib significantly inhibited stress-induced promotion of PDAC xenografts with and without activating mutations in k-ras [37] while low dose aspirin prevented the progression of preneoplastic lesions to PDAC in a transgenic mouse model of mutated k-ras [56] strongly suggest inhibition of COX-2 as a promising strategy for the improvement of clinical outcomes in PDAC undergoing standard cancer therapy. In light of the documented cardiotoxicity of selective COX-2 inhibitors [102], low dose aspirin would be the agent of choice and should be tested alone and in combination with GABA. Low dose aspirin has been safely used for the long-term prevention of cardiovascular disease. Similarly, nutritional supplementation with GABA has served for many years to reduce anxiety and relieve muscle spasms. Both of these agents are therefore also suitable for the prevention of PDAC in individuals at risk.

In summary, sympathetic hyperactivity that drives cardiovascular disease also contributes significantly to PDAC development, progression and resistance to therapy and is enhanced by the additional predominance of stress neurotransmitters produced by PDAC cells and their epithelial precursor cells. While neither disease can be cured, emerging experimental evidence suggests that lessons learned from the long-term management of cardiovascular disease can be successfully utilized to improve survival rates of PDAC patients and to prevent the development of PDAC in individuals at risk.

Acknowledgement
Financially supported by grants R01CA042829, R01CA130888 and R11CA144640 with the National Cancer Institute, National Institutes of Health.

References
1. Almhecka K, Philip PA (2011) Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol 12: 111-125.
2. Lowenthal EA, Maisonneuve P (2005) Risk factors for pancreatic cancer. J Cell Biochem 95: 649-656.
3. Hamer M, Chida Y, Molloy GJ (2009) Psychological distress and cancer mortality. J Psychosom Res 66: 265-268.
4. Zabora J, BrintzenhofesZoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psychooncology 10: 19-28.
5. Clark KL, Loscalzo M, Trask PC, Zabora J, Philip EJ (2010) Psychological distress in patients with pancreatic cancer--an understudied group. Psychooncology 19: 1313-1320.
6. Haas SL, Ye W, Lühr JM (2012) Alcohol consumption and digestive tract cancer. Curr Opin Clin Nutr Metab Care 15: 457-467.
7. Herreros-Villanueva M, Hijena E, Bañales JM, Cosme A, Bujanda L (2013) Alcohol consumption on pancreatic diseases, World J Gastroenterol 19: 638-647.
8. Robinson JD, Cinciripini PM (2006) The effects of stress and smoking on catecholaminergic and cardiovascular response. Behav Med 32: 13-18.
9. Schuller HM (2009) Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 9: 195-206.
10. Schuller HM, Al-Wadei HA, Ullah MF, Plummer HK 3rd (2012) Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogenesis 33: 191-196.
11. Lefkowitz RJ, Hoffman BB, Taylor P (1990) Neurohumoral transmission: The autonomic and somatic motor nervous systems. In: Goodman Gilman A, Rail TW, Nies AS, Taylor P The pharmacological basis of therapeutics 8th edn. Oxford, Pergamon Press 187-122.
12. Lindstrom J, Anand R, Gerzanchiz V, Peng X, Wang F, et al. (1996) Structure and function of neuronal nicotinic acetylcholine receptors. Prog Brain Res 109: 125-137.
13. Borroto-Escuela DO, Agnati LF, Fuxe K, Ciruela F (2012) Muscarinic acetylcholine receptor-interacting proteins (mAChRIPs): targeting the receptorsome. Curr Drug Targets 13: 53-71.
14. McEwen BS (2000) The neurobiology of stress: from serendipity to clinical relevance. Brain Res 886: 172-189.
15. Ramos BP, Arntsen AF (2007) Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 113: 523-536.
16. Hoffman BB, Lefkowitz RJ (1990) Cathelochalines and sympathomimetic drugs. In: Goodman Gilman A, Rail TW, Nies AS, Taylor P The pharmacological basis of therapeutics 8th edn. Oxford, Pergamon Press 187-122.
17. Lefkowitz RJ (2007) Seven transmembrane receptors: something old, something new. Acta Physiol (Oxf) 190: 9-19.
18. Zheng M, Zhu W, Han Q, Xiao RP (2005) Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol Ther 108: 257-268.
19. Al-Wadei MH, Al-Wadei HA, Schuller HM (2012) Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors L3, L5, and L7. Mol Cancer Res 10: 239-249.
20. Ackerman MS, Roskes WR, Heck RJ, Korc M (1989) Identification and characterization of muscarinic receptors in cultured human pancreatic adenocarcinoma cell line (BxPC-3). Pancreas 9: 599-605.
21. Shen SG, Zhang D, Hu HT, Li JH, Wang Z, et al. (2008) Effects of alpha-adrenoceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol 14: 2358-2363.
22. Weddle DL, Tithoff P, Williams M, Schuller HM (2001) Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 22: 473-479.
23. Hu HT, Ma QY, Zhang D, Shen SG, Han L, et al. (2010) HIF-1alpha links beta-adrenoceptor agonists and pancreatic cancer cells under normoxic condition. Acta Pharmacol Sin 31: 102-110.
24. Lin X, Luo K, Lv Z, Huang J (2012) Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology 59: 584-588.
25. Spindel ER (2012) Muscarinic receptor agonists and antagonists: effects on cancer. Handb Exp Pharmacol : 451-468.
26. Wong HP, Yu L, Lam EK, Tai EK, Wu WK, et al. (2007) Nicotine promotes cell proliferation via alpha7 nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol 221: 261-267.
27. Al-Wadei HA, Al-Wadei MH, Schuller HM (2012) Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One 7: e29915.
28. Al-Wadei HA, Al-Wadei MH, Masi T, Schuller HM (2010) Chronic exposure to estrogen and the tobacco carcinogen NNK cooperatively modulates nicotinic receptors in small airway epithelial cells. Lung Cancer 69: 33-38.
29. Lingard JM, al-Nakkash L, Argent BE (1994) Acetylcholine, ATP, bombesin, and cholecystokinin stimulate 125I efflux from a human pancreatic adenocarcinoma cell line (BxPC-3). Pancreas 9: 599-605.
30. Askard MD, Tsao MS, Schuller HM (2005) The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelial cells through beta-adrenergic transactivation of EGFR receptors. J Cancer Res Clin Oncol 131: 639-648.
31. Grau M, Soley M, Ramírez I (1997) Interaction between adrenaline and epidermal growth factor in the control of liver glycogenolysis in mouse. Endocrinology 138: 2601-2609.
32. Shao J, Lee SB, Guo H, Evers BM, Sheng H (2003) Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63: 5218-5223.
33. Askari MD, Tsao MS, Cekanova M, Schuller HM (2006) Ethanol and the tobacco-specific carcinogen, NNK, contribute to signaling in immortalized human pancreatic duct epithelial cells. Pancreas 33: 53-62.
34. Schuller HM, Al-Wadei HA, Majidi M (2008) GABA B receptor is a novel drug target for pancreatic cancer. Cancer 112: 767-778.
35. Papageorgio C, Perry MC (2007) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Cancer Invest 25: 647-657.
36. Ding XZ, Tong WG, Adrian TE (2001) Cyclooxygenases and lipoxigenases as potential targets for treatment of pancreatic cancer. Pancreatology 1: 291-299.
37. Al-Wadei HA, Al-Wadei MH, Ullah MF, Schuller HM (2012) Colecitob and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS One 7: e43376.
38. Shan T, Ma Q, Zhang D, Guo K, Liu H, et al. (2011) P2-adreceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 665: 1-7.
39. Zhang D, Ma Q, Shen S, Hu H (2009) Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adreceptor antagonist’s anticancer effect in pancreatic cancer. Pancreas 38: 94-100.
40. Al-Wadei MH, Al-Wadei HA, Schuller HM (2012) Effects of chronic nicotine on the autocrine regulation of pancreatic cancer cells and pancreatic duct epithelial cells by stimulatory and inhibitory neurotransmitters. Carcinogenesis 33: 1745-1753.
41. Govind AP, Vezina P, Green WN (2009) Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 78: 756-765.
42. Barik J, Wonnacott S (2006) Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol 69: 618-628.
43. Hecht SS (2008) Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 21: 160-171.
44. Lisiansky V, Naumov I, Shapiro S, Kazanov D, Starr A, et al. (2012) Gene therapy of pancreatic cancer targeting the K-Ras oncogene. Cancer Gene Ther 19: 862-869.
45. Schuller HM, Orloff M (1998) Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 55: 1377-1384.
46. Arredondo J, Chernyavsky AI, Grando SA (2006) Nicotinic receptors mediate lumogenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells. Cancer Biol Ther 5: 511-517.

47. Schuller HM, Tilthof PK, Williams M, Plummer H 3rd (1999) The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59: 4510-4515.

48. Wessler I, Kirkpatrick CJ (2008) Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 154: 1558-1571.

49. Al-Wadi HA, Plummer HK 3rd, Schuller HM (2009) Nicotine stimulates pancreatic cancer xenografts by systemic stress in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 30: 506-511.

50. Epperson CN, O’Malley S, Czarkowski KA, Gueorgueva R, Jatlow P, et al. (2005) Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels in rats. J Neurochem 91: 724-732.

51. Schiller HM, Orquera R, Reichert A, Castonguay A (1993) Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 53: 2498-2501.

52. Al-Wadi HA, Al-Wadi MH, Schuller HM (2009) Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 20: 477-482.

53. Schiller HM, Zhang L, Weddle DL, Castonguay A, Walker K, et al. (2002) The cytoxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 128: 525-532.

54. Rao CV, Mohammed A, Janakiram NB, Li Q, Ritchie RL, et al. (2012) Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre)/+;LSL-Kras(G12D)/+ mice. Neoplasia 14: 778-787.

55. Banerjee J, Al-Wadi HA, Schuller HM (2013) Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts. Eur J Cancer 49: 1152-1158.

56. Momi N, Ponnusamy MP, Kaur S, Rachagani S, Kunigal SS, et al. (2013) Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through 3ζ7γ7αγ7 mediated MUC4 upregulation. Oncogene 32: 1384-1395.

57. Treviño JG, Pillai S, Kunigal S, Singh S, Fulp WJ, et al. (2012) Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Neoplasia 14: 1102-1114.

58. Lazar M, Sullivan J, Chipitsyna G, Gong Q, Ng CY, et al. (2010) Involvement of cigarette-degrading and genotoxic changes mediated by nicotine in pancreatic cancer cells. J Gastrointest Surg 14: 1566-1577.

59. Sullivan J, Blair L, Alnajra A, Aziz T, Chipitsyna G, et al. (2011) Expression and regulation of nicotine receptor and opioid receptor isoforms in human pancreatic ductal adenocarcinoma. Histol Histopathol 26: 893-904.

60. Pham H, Chen M, Takahashi H, King J, Reber HA, et al. (2012) Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Pancreas 41: 1306-1315.

61. Park CH, Lee IS, Grippo P, Pandol SJ, Gukovskaya AS, et al. (2013) Akt kinase mediates the prosurvival effect of smoking compounds in pancreatic ductal cells. Pancreas 42: 655-662.

62. Huang XY, Wang HC, Yuan Z, Huang J, Zheng Q (2012) Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of p38/ERK pathway. Hepatogastroenterology 59: 869-873.

63. Guo K, Ma Q, Wang L, Hu H, Li J, et al. (2008) Norepinephrine-induced invasion of pancreatic cancer cells is inhibited by propranolol. Oncol Rep 22: 825-830.

64. Chan C, Lin HJ, Lin J (2008) Stress-associated hormone, norepinephrine, increases proliferation and IL-6 levels of human pancreatic duct epithelial cells and can be inhibited by the dietary agent, sulfafurap. Int J Oncol 33: 415-419.

65. Stock AM, Powe DG, Hahn SA, Troost G, Niggemann B, et al. (2013) Norepinephrine inhibits the migratory activity of pancreatic cancer cells. Exp Cell Res 319: 1744-1758.

66. Wang L, Liu H, Chen X, Zhang M, Xie K, et al. (2012) Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells. PLoS One 7: e45491.

67. Catecholamines–blood (2013) MedlinePlus, National Library of Medicine National Institutes of Health.

68. Esler M, Kaye D (2000) Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev 5: 17-25.

69. Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, et al. (2012) High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/GI-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 126: 697-706.

70. El-Armouche A, Zolik O, Rau T, Eschenhagen T (2003) Inhibitory G-proteins and their role in desensitization of the adenyl cyclase pathway in heart failure. Cardiovasc Res 60: 478-487.

71. Penn RB, Benovic JL (2008) Regulation of heterotrimeric G protein signaling in airway smooth muscle. Proc Am Thorac Soc 5: 47-57.

72. Herrmann-Kleiter N, Thullie N, Pfeifhofer C, Gruber T, Schäfer M, et al. (2006) PKCheta and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes. Blood 107: 4841-4848.

73. Mathieson W, Kirkland S, Leonard R, Thomas GA (2011) Anti-microbial agents and in vitro systems: antibiotics and antimycotics alter the proteome of MCF-7 cells in culture. J Cell Biochem 112: 2170-2178.

74. Demir IE, Friess H, Ceyhan GO (2012) Nerve-cancer interactions in the stromal biology of pancreatic cancer. Front Physiol 3: 97.

75. Guo K, Ma Q, Li J, Wang Z, Shan T, et al. (2013) Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol Cancer Ther 12: 284-273.

76. Gapturst SM, Jacobs EJ, Deka A, McCullough ML, Patel AV, et al. (2011) Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch Intern Med 171: 444-451.

77. Al-Wadi MH, Al-Wadi HA, Schuller HM (2013) Gamma-amino butyric acid (GABA) prevents the induction of nicotinic receptor-regulated signaling by chronic ethanol in pancreatic cancer cells and normal duct epithelia. Cancer Prev Res (Phila) 6: 139-148.

78. Hendrickson LM, Guildford MJ, Tapper AR (2013) Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry 4: 29.

79. Rahman S (2013) Nicotinic receptors as therapeutic targets for drug addictive disorders. CNS Neurol Drug Disc Trends 12: 633-640.

80. Ward ST, Dangi-Garimella S, Shields MA, Collander BA, Siddiqui MA, et al. (2011) Ethanol differentially regulates snail family of transcription factors and invasion of premalignant and malignant pancreatic ductal cells. J Cell Biochem 112: 2940-2943.

81. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS (1988) Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and areca-derived N-nitrosamines. Cancer Res 48: 6912-6917.

82. Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18: 1201-1206.

83. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, et al. (2013) Autonomic nerve development contributes to prostate cancer progression. Science 341: 1236361.

84. Schuller HM (2008) Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 19: 655-671.

85. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, et al. (2013) Improved Chemosensitivity of Human Pancreatic Cancer Cell Lines by the β2-adrenergic Agonist Isoproterenol and Preclinical Relevance for the β2-Adrenergic Agonist MDL-124,746.
survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24: 1312-1319.

88. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, et al. (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1: 628-638.

89. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, et al. (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29: 2645-2652.

90. Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL (2013) Use of ß-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 73: 250-259.

91. De Giorgi V, Grazzini M, Gandini S, Benemei S, Asbury CD, et al. (2012) ß-adrenergic-blocking drugs and melanoma: current state of the art. Expert Rev Anticancer Ther 12: 1461-1467.

92. Diaz ES, Karlan BY, Li AJ (2012) Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 127: 375-378.

93. Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, et al. (2013) Impact of beta blocker medication in patients with platinum-sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol 129: 463-466.

94. Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, et al. (2011) Does ß-adrenergic receptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 72: 157-161.

95. Malpas SC (2010) Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 90: 513-557.

96. Sheppard BJ, Williams M, Plummer HK, Schuller HM (2000) Activation of voltage-operated Ca\(^2+\)-channels in human small cell lung carcinoma by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Int J Oncol 16: 513-518.

97. Michel MC, Pingsmann A, Beckeringh JJ, Zerkowski HR, Doetsch N, et al. (1988) Selective regulation of beta 1- and beta 2-adrenoceptrors in the human heart by chronic beta-adrenoceptor antagonist treatment. Br J Pharmacol 94: 685-692.

98. Brodde OE, Daul A, Michel MC (1990) Subtype-selective modulation of human beta 1- and beta 2-adrenoceptor function by beta-adrenoceptor agonists and antagonists. Clin Physiol Biochem 8 Suppl 2: 11-17.

99. Schuller HM, Al-Wadei HA (2012) Beta-adrenergic signaling in the development and progression of pulmonary and pancreatic adenocarcinoma. Curr Cancer Ther Rev 8: 116-127.

100. Wenjuan Y, Yujun L, Ceng Y (2013) Association of single nucleotide polymorphisms of ß2-adrenergic receptor gene with clinicopathological features of pancreatic carcinoma. Acta Histochim 115: 198-203.

101. Takehara A, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, et al. (2007) Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res 67: 9704-9712.

102. Brophy JM (2007) Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 23: 617-624.